Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children
On Thursday, the U.S. Food and Drug Administration (FDA) approved an expanded label for Vertex Pharmaceuticals Incorporated ‘s (NASDAQ: VRTX ) Casgevy (exagamglogene autotemcel). The approval allows Casgevy to be used in patients aged 2 years and older with sickle cell disease (SCD), accompanied by recurrent vaso-occlu